A "Trojan Horse" Strategy: The Preparation of Bile Acid-Modifying Irinotecan Hydrochloride Nanoliposomes for Liver-Targeted Anticancer Drug Delivery System Study

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Feb 25

PMID 36838565

Authors

Tao Zhou

Yushi Liu

Kelu Lei

JunJing Liu

Minghao Hu

Li Guo

Yiping Guo

Qiang Ye

Affiliations

Soon will be listed here.

Abstract

The bile acid transport system is a natural physiological cycling process between the liver and the small intestine, occurring approximately 6-15 times during the day. There are various bile acid transporter proteins on hepatocytes that specifically recognize bile acids for transport. Therefore, in this paper, a novel liposome, cholic acid-modified irinotecan hydrochloride liposomes (named CA-CPT-11-Lip), was prepared based on the "Trojan horse" strategy. The liposomes preparation process was optimized, and some important quality indicators were investigated. The distribution of irinotecan hydrochloride in mice was then analyzed by high-performance liquid chromatography (HPLC), and the toxicity of liposomes to hepatocellular carcinoma cells (HepG-2) was evaluated in vitro. As a result, CA-CPT-11-Lip was successfully prepared. It was spherical with a particle size of 154.16 ± 4.92 nm, and the drug loading and encapsulation efficiency were 3.72 ± 0.04% and 82.04 ± 1.38%, respectively. Compared with the conventional liposomes (without cholic acid modification, named CPT-11-Lip), CA-CPT-11-Lip had a smaller particle size and higher encapsulation efficiency, and the drug accumulation in the liver was more efficient, enhancing the anti-hepatocellular carcinoma activity of irinotecan hydrochloride. The novel nanoliposome modified by cholic acid may help to expand the application of irinotecan hydrochloride in the treatment of hepatocellular carcinoma and construct the drug delivery system mode of drug liver targeting.

Citing Articles

A Novel Delivery System for the Combined Use of Natural Ingredients: The Preparation of Berberine Hydrochloride-Matrine Liposomes and Preliminary Exploration of Their Anti-Tumor Activity.

Xu M, Ye Z, Liu J, Zhu S, Chen Y, Cai J Molecules. 2024; 29(21).

PMID: 39519850 PMC: 11547310. DOI: 10.3390/molecules29215210.

Nanoliposomes Permeability in a Microfluidic Drug Delivery Platform across a 3D Hydrogel.

Peyret C, Manousaki A, Bouguet-Bonnet S, Stratakis E, Sanchez-Gonzalez L, Kahn C Pharmaceutics. 2024; 16(6).

PMID: 38931887 PMC: 11207390. DOI: 10.3390/pharmaceutics16060765.

Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer.

Abdellatif A, Alshubrumi A, Younis M AAPS PharmSciTech. 2024; 25(1):23.

PMID: 38267656 DOI: 10.1208/s12249-024-02734-9.

References

Chamseddine A, Ducreux M, Armand J, Paoletti X, Satar T, Paci A . Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharmacol Ther. 2019; 199:1-15. DOI: 10.1016/j.pharmthera.2019.03.002. View

Seyfried T, Huysentruyt L . On the origin of cancer metastasis. Crit Rev Oncog. 2012; 18(1-2):43-73. PMC: 3597235. DOI: 10.1615/critrevoncog.v18.i1-2.40. View

Javed Ansari M, Rahman M, Alharbi K, Altowayan W, Ali A, Almalki W . Hispolon-Loaded Liquid Crystalline Nanoparticles: Development, Stability, In Vitro Delivery Profile, and Assessment of Hepatoprotective Activity in Hepatocellular Carcinoma. ACS Omega. 2022; 7(11):9452-9464. PMC: 8945187. DOI: 10.1021/acsomega.1c06796. View

Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara T . High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy. Med Oncol. 2019; 36(7):63. DOI: 10.1007/s12032-019-1288-7. View

Nayak D, Boxi A, Ashe S, Thathapudi N, Nayak B . Stavudine loaded gelatin liposomes for HIV therapy: Preparation, characterization and in vitro cytotoxic evaluation. Mater Sci Eng C Mater Biol Appl. 2017; 73:406-416. DOI: 10.1016/j.msec.2016.12.073. View

Zhou T, Tang X, Zhang W, Feng J, Wu W . Preparation and and evaluations of 10-hydroxycamptothecin liposomes modified with stearyl glycyrrhetinate. Drug Deliv. 2019; 26(1):673-679. PMC: 6610527. DOI: 10.1080/10717544.2019.1636422. View

Sreekanth V, Bansal S, Motiani R, Kundu S, Muppu S, Majumdar T . Design, synthesis, and mechanistic investigations of bile acid-tamoxifen conjugates for breast cancer therapy. Bioconjug Chem. 2013; 24(9):1468-84. DOI: 10.1021/bc300664k. View

Soe Z, Poudel B, Nguyen H, Thapa R, Ou W, Gautam M . Folate-targeted nanostructured chitosan/chondroitin sulfate complex carriers for enhanced delivery of bortezomib to colorectal cancer cells. Asian J Pharm Sci. 2020; 14(1):40-51. PMC: 7032194. DOI: 10.1016/j.ajps.2018.09.004. View

Shnoudeh A, Qadumii L, Zihlif M, Al-Ameer H, Salou R, Jaber A . Green Synthesis of Gold, Iron and Selenium Nanoparticles Using Phytoconstituents: Preliminary Evaluation of Antioxidant and Biocompatibility Potential. Molecules. 2022; 27(4). PMC: 8875721. DOI: 10.3390/molecules27041334. View

10.

Dobson P, Kell D . Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat Rev Drug Discov. 2008; 7(3):205-20. DOI: 10.1038/nrd2438. View

11.

Rajpoot K, Jain S . Irinotecan hydrochloride trihydrate loaded folic acid-tailored solid lipid nanoparticles for targeting colorectal cancer: development, characterization, and cytotoxicity study using HT-29 cells. J Microencapsul. 2019; 36(7):659-676. DOI: 10.1080/02652048.2019.1665723. View

12.

Liu M, Jin S, Yan H, Du S . Effect of oxymatrine HSPC liposomes on improving bioavailability, liver target distribution and hepatoprotective activity of oxymatrine. Eur J Pharm Sci. 2017; 104:212-220. DOI: 10.1016/j.ejps.2017.03.048. View

13.

Oyaga-Iriarte E, Insausti A, Sayar O, Aldaz A . Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. J Pharmacol Sci. 2019; 140(1):20-25. DOI: 10.1016/j.jphs.2019.03.004. View

14.

Zhu Y, Liang J, Gao C, Wang A, Xia J, Hong C . Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. J Control Release. 2020; 330:641-657. DOI: 10.1016/j.jconrel.2020.12.036. View

15.

Bailly C . Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019; 148:104398. DOI: 10.1016/j.phrs.2019.104398. View

16.

Lei K, Yuan M, Zhou T, Ye Q, Zeng B, Zhou Q . Research progress in the application of bile acid-drug conjugates: A "trojan horse" strategy. Steroids. 2021; 173:108879. DOI: 10.1016/j.steroids.2021.108879. View

17.

Karim S, Akhter M, Burzangi A, Alkreathy H, Alharthy B, Kotta S . Phytosterol-Loaded Surface-Tailored Bioactive-Polymer Nanoparticles for Cancer Treatment: Optimization, In Vitro Cell Viability, Antioxidant Activity, and Stability Studies. Gels. 2022; 8(4). PMC: 9026838. DOI: 10.3390/gels8040219. View

18.

Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6(10):789-802. DOI: 10.1038/nrc1977. View

19.

Kciuk M, Marciniak B, Kontek R . Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. Int J Mol Sci. 2020; 21(14). PMC: 7404108. DOI: 10.3390/ijms21144919. View

20.

Deng F, Bae Y . Bile acid transporter-mediated oral drug delivery. J Control Release. 2020; 327:100-116. PMC: 7606772. DOI: 10.1016/j.jconrel.2020.07.034. View